bullish
SK Biopharmaceuticals (326030 KS): Highest Performance in 2021; Pipeline Progress Entails Visibility
305 Views16 Mar 2022 16:19
SUMMARY
- SK Biopharmaceuticals Co Ltd (326030 KS) surpassed KRW400 billion sales last year, the highest since inception. The company targets more than doubling sales this year, through global expansion of cenobamate.
- The company is expected to launch its third commercial drug, carisbamate (currently in phase 3 trial) in global market in 2025.
- On the back of robust 2021 financial performance, SK Biopharmaceuticals shares have recovered and reached to two-month high, thereby offering an attractive and confirming buying opportunity.
Related Insights
More »- SK Biopharmaceuticals (326030 KS): Records Maiden Profit in 2024; Momentum to Continue
- SK Biopharmaceuticals (326030 KS): Sequential Profit Decline in 3Q; Long-Term Growth Prospect Intact
- Key Flow Trading Opportunities After KRX Suddenly Added POSCO Holdings to the BBIG Battery Mix
- KRX’s September Major Rebalancing Events: Why We Should Focus on KRX BBIG
- SK Biopharmaceuticals (326030 KS): Resumption of US Sales Growth Raises Hope for Annual Profit
Trending Collections
More »Trending Insights
More »- NIFTY 50 Tactical Outlook (Post-Easter Targets)
- TSMC. Full Steam Ahead Despite Tariff Threats & China Bans. For Now.
- The Key to Japanese Equity Outperformance Is a Step Beyond Shareholder Returns
- Still Bearish/Cautious; Stick With Defensives; Emerging Market Opportunities
- TSLA Earnings: Volatility Setup and Post-Release Price Behavior
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- SK Biopharmaceuticals (326030 KS): Xcopri US Sales Doubled in 2022; More Stream Still Left05 May 2023
- SK Biopharmaceuticals (326030 KS): Global Expansion to Accelerate Growth Trajectory of Epilepsy Drug03 Feb 2023
- SK Biopharmaceuticals (326030 KS): Strong Xcopri US Sales Not Reflected in Share Price Performance27 Oct 2022
- SK Biopharmaceuticals (326030 KS): Highest Performance in 2021; Pipeline Progress Entails Visibility16 Mar 2022
- SK Biopharmaceuticals (326030 KS): A Promising Play on Central Nervous System Disorders24 Dec 2021
x